SLAMF6 Human

Signaling Lymphocytic Activation Molecule Family member 6 (SLAMF6), also known as CD352, is a homophilic receptor belonging to the immunoglobulin (Ig) superfamily. It is encoded by the SLAMF6 gene in humans and plays a crucial role in the regulation of immune responses .

SLAMF6 is characterized by its extracellular domain, which contains Ig-like domains, a transmembrane region, and a cytoplasmic tail. The receptor is constitutively expressed on various immune cells, including T cells, B cells, natural killer (NK) cells, and dendritic cells . Its expression is upregulated upon activation of these cells, indicating its involvement in immune modulation .

SLAMF6 functions as a co-stimulatory molecule that enhances the activation and proliferation of T cells and NK cells. It is involved in the formation of immunological synapses, which are critical for effective immune responses. SLAMF6 also plays a role in the regulation of cytokine production and the maintenance of immune homeostasis .

Recent studies have highlighted the role of SLAMF6 as an immune checkpoint regulator. It has been shown to be involved in the exhaustion of CD8+ T cells within the tumor microenvironment. T-cell exhaustion is characterized by a loss of proliferative capacity and impaired effector functions, which can hinder effective antitumor responses .

Targeting SLAMF6 has emerged as a potential therapeutic strategy for cancer immunotherapy. Inhibiting SLAMF6 can enhance the cytotoxic functions of CD8+ T cells and improve their ability to eradicate tumors. This approach has shown promise in preclinical models of chronic lymphocytic leukemia (CLL) and melanoma .

Human recombinant SLAMF6 is produced using recombinant DNA technology, which involves the insertion of the SLAMF6 gene into an expression vector, followed by the expression of the protein in a suitable host system. Recombinant SLAMF6 is used in various research applications to study its function and therapeutic potential.